US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Latest News about Fabio Chianelli

Recent news which mentions Fabio Chianelli

Ketamine Could Soon Be A Treatment Option For This Rare Genetic Neurological Disorder
Tickers PHRRF
Tags Psychedelics Contracts Penny Stocks
From Benzinga
Ketamine for Parkinson's Disease, PharmaTher Holdings Announces Grant of U.S. Patent To Cover It
Tickers PHRRF
Tags United States Patent and Trademark Office Market News University of Arizona
From Benzinga
PharmaTher Provides Business Highlights And Releases Audited Annual Financials
Tickers PHRRF
Tags Market News Markets Fabio Chianelli
From Benzinga
PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson's Disease
Tickers PHRRF
Tags PharmaTher Holdings Cannabis Ketamine
From Benzinga
Intradermal Ketamine Patch Completes Pre-Clinical Phase, Advances To Clinical Studies
Tickers PHRRF
Tags Psychedelics KETARX Global
From Benzinga
PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment
Tickers PHRRF
Tags Markets Legal Psychedelics
From Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Tickers AGNPF ALID ATAI AWKNF
Tags CYBN BMBIF GHRS
From Benzinga